v3.26.1
Financial Instruments (Tables)
6 Months Ended
Jun. 30, 2026
Disclosure of detailed information about financial instruments [abstract]  
Schedule of level 3 reconciliation of assets
The table below shows the fair value measurements by level for Genmab’s financial assets measured at fair value through profit or loss:
NoteJune 30, 2026December 31, 2025
Assets Measured at Fair ValueLevel 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Interest rate swaps1,8— 10 — 10 — — — — 
Other investments25 36 26 37 
Schedule of fair value changes on Level 3 investments of liabilities
There were no transfers into or out of Level 3 during the first six months of 2026 or 2025. Acquisitions (capital calls), distributions and fair value changes on Level 3 investments in 2026 and 2025 were as follows:
Other Investments
Fair value at December 31, 202425
Acquisitions3
Fair value changes(3)
Fair value at June 30, 202525
Acquisitions1
Fair value at December 31, 202526
Acquisitions4
Distributions(5)
Fair value at June 30, 202625
Schedule of fair value changes on Level 3 investments of assets
There were no transfers into or out of Level 3 during the first six months of 2026 or 2025. Acquisitions (capital calls), distributions and fair value changes on Level 3 investments in 2026 and 2025 were as follows:
Other Investments
Fair value at December 31, 202425
Acquisitions3
Fair value changes(3)
Fair value at June 30, 202525
Acquisitions1
Fair value at December 31, 202526
Acquisitions4
Distributions(5)
Fair value at June 30, 202625